Press Releases | Page 17 of 42

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

“Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]” BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15… read more

Figure 2: Analysis of immune cell subsets during neoadjuvant therapy.

Oncotarget

Durvalumab and Tremelimumab Before Surgery in Patients With HR+/HER2-negative Breast Cancer

March 27, 2024

“[...] this trial was stopped early after 3 of the first 8 enrolled patients experienced immunotherapy-related toxicity or suspected disease progression [...]” BUFFALO, NY- March 27, 2024 – A new… read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

“[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.” BUFFALO, NY- March 25, 2024 – A new research… read more

Figure 8: Major analytical performance measurements of the NeXT Personal® assay.

Oncotarget

Analytical Validation of an Ultra-sensitive Personalized Circulating Tumor DNA Assay: NeXT Personal®

March 20, 2024

“These results suggest strong potential for clinical use of the assay in ctDNA monitoring of solid tumor cancers.” BUFFALO, NY- March 20, 2024 – A new research paper was published… read more

Figure 2: Preemptive combinations. (A) EGFR-Mutant-Driven NSCLC. See text. (B) METex14-Driven NSCLC. See text.

Oncotarget

“From Osimertinib to Preemptive Combinations” by Dr. Blagosklonny

March 19, 2024

“Here I will re-introduce the notion of preemptive combinations (PC) of targeted drugs.” BUFFALO, NY- March 19, 2024 – A new research perspective was published by Mikhail V. Blagosklonny M.D.,… read more

Figure 2: A comparative analysis of G4 landscape in cultured cells using AbC G4-ChIP. antibody

Oncotarget

A New Antibody Capture Method Reveals G-quadruplex Landscape and its Regulation

March 18, 2024

“[...] we present an improved method for G4 landscape determination and by applying it we show that sequence property-specific constraints of the nuclear environment mitigate G4 formation.” BUFFALO, NY- March… read more

Oncotarget

Oncotarget at AACR Annual Meeting 2024

March 11, 2024

BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Oncotarget is one of… read more

Figure 7: ER stress signaling plays an important role in mediating GZ17-6.02/bortezomib lethality

Oncotarget

GZ17-6.02 With Proteasome Inhibitors Kills Multiple Myeloma Cells

March 6, 2024

“We believe that developing GZ17-6.02 as a novel multiple myeloma agent potentially opens up a multitude of novel opportunities to develop therapeutic approaches which will prolong patient survival.” BUFFALO, NY-… read more

Figure 2: Immunoblot assessment of effects on cell-cycle, pro- and anti-apoptosis signaling events mediated by Sacituzumab govitecan plus platinum-based chemotherapeutics in human TNBC, SCLC, and UBC tumor-lines.

Oncotarget

Sacituzumab Govitecan Plus Platinum-based Chemotherapy in Breast, Bladder, and Lung Carcinomas

March 4, 2024

“[...] these results support the rationale and potential for favorable clinical outcomes of combining SG therapy with platinum-based chemotherapeutics in solid tumors.” BUFFALO, NY- March 4, 2024 – A new… read more

Oncotarget

BRCA1 and BRCA2 in a Cohort of Ovarian Cancer Patients From the Salento Peninsula

February 28, 2024

“Ovarian cancer (OC) is the third most prevalent type of gynecologic cancer affecting women after cervical and uterine cancer [1]. It is also considered the most fatal of all gynecological… read more